Venous thromboembolism in cancer patients;Venöse thrombembolien bei tumorpatienten

Hamostaseologie

Volumn 31, Issue 4, 2011, Pages 281-290

  Pabinger, I ^a   Alt Epping, B ^b   Demarmels Biasutti, F ^c   Langer, F ^d   Wormann B ^e   Riess, H ^f  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e Gesellschaft für medizinische Innovation Hämatologie und Onkologie mbH   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cancer; Pulmonary embolism; Tumour; Venous thromboembolism; Venous thrombosis

Indexed keywords

ARTICLE; CANCER PATIENT; GERMANY; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEMORRHAGE; HUMANS; NEOPLASMS; VENOUS THROMBOEMBOLISM;

EID: 84855252487     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-1174     Document Type: Article

References (26)

1. Ay C, Pabinger I. Test predictive of thrombosis in cancer. Thromb Res 2010; 125 (Suppl 2): S12-S15.
2. Ay C, Dunkler D, Marosi C et al. Prediction of venous thrombembolism in cancer patients. Blood 2010; 116: 5377-5372.
3. Carrier M, Le Gal G, Wells PS et al. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism. Ann Int Med 2008; 140: 323-333.
4. Carrier M, Le Gal G, Tay J et al. Thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide and lenalidomide: a systematic review and meta-analysis. Meeting of the American Society of Hematology, Abstract 1090, 2010.
5. Connolly GC, Khorana AK. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res 2010; 125 (Suppl 2): S1-S7.
6. Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009; 27: 4848-4857.
7. Hylek EM. Therapeutic potential of oral factor Xa inhibitors. N Engl J Med 20010; 363: 2559-2561.
8. Kakkar AK. Prevention of venous thromboembolism in the cancer surgical patient. J Clin Oncol 2009; 29: 2881-4884.
9. th ed). Chest 2008; 133: 454S-545S.
10. Khorana AA, Connolly GC. Assessing risk for venous thromboembolism in the patients with cancer. J Clin Oncol 2009; 27: 4839-4847.
11. Lee AY. Anticoagulation in the treatment of established venous thromboembolism in patients with cancer. J Clin Oncol 2009; 27: 4895-4901.
12. Le Gal G, Righini M, Roy PM et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 2006; 144: 165-171.
13. Lewandowski B, Kovacs MJ. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003; 349: 1227-1235.
14. Lyman GH, Khorana AA, Falanga A et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
15. Mandala M, Labianca R. Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management. Thromb Res 2010; 125 (Suppl 2): S117-S119.
16. Palumbo A, Rajkumar SV, Dimopoulos MA et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-423.
17. Perry JR, Julian JA, Laperriere NJ et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8: 1959-1965.
18. Piccioli A, Lensing AW, Prins MH et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2004; 2: 884-889.
19. Rana P, Levine MN. Prevention of thrombosis in ambulatory patients with cancer. J Clin Oncol 2009; 29: 4885-4888.
20. Riess H, Pelzer U, Opitz M et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. J Clin Oncol 2010; 28 (Suppl): Abstract 4033.
21. S2-Leitlinie zur Diagnostik und Therapie der Venenthrombose und der Lungenembolie in Deutschland 2010. http://www.awmf.org/leitlinien/detail/ll/065-002.html.
22. Shivakumar SP, Anderson DR, Couban S. Catheterassociated thrombosis in patients with malignancy. J Clin Oncol 2009; 27: 4858-4864.
23. Streiff MB. The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb Res 2010; 125 (Suppl 2): S128-S133.
24. Tran QNH. Role of palliative low-molecular-weight heparin for treating venous thromboembolism in patients with advanced cancer. Am J Hosp Palli Med 2010; 27: 416-419.
25. Wells PS, Hirsh J, Anderson DR et al. Accuracy of clinical assessment of deep vein thrombosis. Lancet 1995; 345: 1326-1330.
26. Wells PS, Ginsberg JS, Anderson DR et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med 1998; 129: 997-1005.